CN114805366A - 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物 - Google Patents

作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物 Download PDF

Info

Publication number
CN114805366A
CN114805366A CN202210507333.8A CN202210507333A CN114805366A CN 114805366 A CN114805366 A CN 114805366A CN 202210507333 A CN202210507333 A CN 202210507333A CN 114805366 A CN114805366 A CN 114805366A
Authority
CN
China
Prior art keywords
alkyl
compound
chloro
heteroaryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210507333.8A
Other languages
English (en)
Chinese (zh)
Inventor
李菁
赵海波
王志伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN114805366A publication Critical patent/CN114805366A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202210507333.8A 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物 Pending CN114805366A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2016108897 2016-12-07
CNPCT/CN2016/108897 2016-12-07
CN201780076039.3A CN110267959B (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780076039.3A Division CN110267959B (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物

Publications (1)

Publication Number Publication Date
CN114805366A true CN114805366A (zh) 2022-07-29

Family

ID=62491736

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210507333.8A Pending CN114805366A (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
CN201780076039.3A Expired - Fee Related CN110267959B (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780076039.3A Expired - Fee Related CN110267959B (zh) 2016-12-07 2017-12-07 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物

Country Status (16)

Country Link
US (2) US11136323B2 (cg-RX-API-DMAC10.html)
EP (1) EP3551630A4 (cg-RX-API-DMAC10.html)
JP (2) JP7064495B2 (cg-RX-API-DMAC10.html)
KR (1) KR20190091339A (cg-RX-API-DMAC10.html)
CN (2) CN114805366A (cg-RX-API-DMAC10.html)
AU (2) AU2017372377B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019011847A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045959A1 (cg-RX-API-DMAC10.html)
EA (1) EA201991355A1 (cg-RX-API-DMAC10.html)
IL (2) IL266986B (cg-RX-API-DMAC10.html)
MX (1) MX394882B (cg-RX-API-DMAC10.html)
NZ (1) NZ754944A (cg-RX-API-DMAC10.html)
SG (1) SG10201912192RA (cg-RX-API-DMAC10.html)
TW (2) TWI762534B (cg-RX-API-DMAC10.html)
WO (1) WO2018103688A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201903286B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394882B (es) 2016-12-07 2025-03-24 Beigene Ltd Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
NZ761680A (en) * 2017-09-08 2023-03-31 Beigene Ltd Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
JP2024521763A (ja) * 2021-05-27 2024-06-04 ベイジーン スウィッツァーランド ゲーエムベーハー Pi3kデルタ阻害剤の塩、その結晶形態、調製方法、及び使用
TW202327611A (zh) * 2021-09-14 2023-07-16 英屬開曼群島商百濟神州有限公司 使用btk抑制劑和p13激酶抑制劑的組合治療癌症之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2372694T3 (es) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
NZ596185A (en) * 2009-04-16 2013-01-25 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
US8653089B2 (en) 2011-02-09 2014-02-18 F. Hoffmann-La Roche Ag Heterocyclic compounds and methods of use
CA2860723A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
KR20160013204A (ko) * 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
SMT202100674T1 (it) 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
MX394882B (es) 2016-12-07 2025-03-24 Beigene Ltd Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta)
NZ761680A (en) 2017-09-08 2023-03-31 Beigene Ltd Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors

Also Published As

Publication number Publication date
IL266986A (en) 2019-07-31
SG10201912192RA (en) 2020-02-27
ZA201903286B (en) 2021-01-27
JP7064495B2 (ja) 2022-05-10
TW202233190A (zh) 2022-09-01
AU2022203737A1 (en) 2022-06-23
NZ754944A (en) 2023-02-24
US11725012B2 (en) 2023-08-15
MX2019006612A (es) 2019-08-01
US20220098202A1 (en) 2022-03-31
EP3551630A4 (en) 2020-07-15
IL290419B (en) 2022-10-01
IL266986B (en) 2022-03-01
WO2018103688A1 (en) 2018-06-14
EP3551630A1 (en) 2019-10-16
JP2022090051A (ja) 2022-06-16
CA3045959A1 (en) 2018-06-14
CN110267959B (zh) 2022-05-27
TWI762534B (zh) 2022-05-01
KR20190091339A (ko) 2019-08-05
TW201833113A (zh) 2018-09-16
MX394882B (es) 2025-03-24
EA201991355A1 (ru) 2019-11-29
IL290419B2 (en) 2023-02-01
AU2017372377A1 (en) 2019-07-18
JP2020500909A (ja) 2020-01-16
US11136323B2 (en) 2021-10-05
AU2017372377B2 (en) 2022-03-03
CN110267959A (zh) 2019-09-20
IL290419A (en) 2022-04-01
BR112019011847A2 (pt) 2019-10-29
US20190367523A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
CN114787161B (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN110267959B (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
KR101921486B1 (ko) PARP억제제인 4H-피라졸로[1,5-a]벤즈이미다졸 화합물의 아날로그
CN102015705B (zh) 稠合的杂环衍生物及其用途
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
CN114341127A (zh) 作为hpk1抑制剂的氨基吡嗪化合物及其用途
CN120659784A (zh) 作为c-Kit激酶抑制剂的化合物和组合物
CN112313234B (zh) 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物
TWI817956B (zh) 咪唑並[1,5-A]吡嗪衍生物作爲PI3Kδ 抑制劑
TW202438054A (zh) 作為MTA-協同PRMT5抑制劑的5-胺基-6,8-二氫-1H-呋喃并[3,4-d]吡咯并[3,2-b]吡啶-2-甲醯胺衍生物
JP2021504334A (ja) ピラゾロピリジノン化合物
JP2020525469A (ja) 新規キノリノン化合物
CN107848971B (zh) 杂环化合物
WO2024067445A1 (zh) 新型prmt5抑制剂及其应用
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
HK40008309A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
RU2806751C2 (ru) Соединения на основе пиразолопиридинона
HK40036174A (en) Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
HK40002986A (zh) 吡啶并嘧啶酮cdk2/4/6抑制剂
UA101021C2 (uk) Конденсована гетероциклічна похідна та її застосування

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination